If you are wondering which test would be best for cervical cancer screening, this clinical trial may contain some important information. The clinical trial investigates the effectiveness of the human papillomavirus testing-based cervical cancer screening protocol for women and compared it to the traditional liquid-based cytology.
Cervical cancer is the fourth most common cancer in women worldwide, and it is caused by the Human Papillomavirus (HPV). Cervical cancer screening programs that employ repeated cytology testing of the adult female population with appropriate follow-up have reduced cervical cancer incidence significantly.
The large difference in cervical cancer incidence between countries with and without established screening programs represents indirect evidence of their effectiveness. Many countries offer cervical cancer screening for all women aged between 25 and 69 years, and it has been shown to reduce the incidence and mortality of cervical cancer. The discovery of the relationship between HPV infection with cervical cancer has led to the development of HPV-based tests for cervical cancer screening. However, strong clinical data on their effectiveness is required.
Clinical TrialA team of researchers in Norway conducted a clinical study to evaluate the effectiveness of a new cervical cancer screening protocol that uses primary HPV testing for women aged between 34 and 69 years.
The trial involved more than 157,447 women aged between 34 and 69 years who were screened for cervical cancer using either the new primary HPV testing-based protocol or the traditional cytology-based screening protocol. These women were followed-up for 18 months. The primary endpoint of the study was the detection of cervical intraepithelial neoplasia (CIN) or cancer in the two screening groups.